Uncomplicated Urinary Tract Infection Treatment Market 2024 - Share, Ongoing Trends, Size, Growth Rate And Key Players
Global uncomplicated urinary tract infection treatment market size is expected to reach $9.16 billion by 2028 at a rate of 10.6%, segmented as by drug class, gepotidacin, probenecid, sulfonamide, tetracycline, nitrofuran
sai subhash Share this Post to earn Money ( Upto ₹100 per 1000 Views )
The Uncomplicated Urinary Tract Infection Treatment Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Uncomplicated Urinary Tract Infection Treatment Market:
According to The Business Research Company’s Uncomplicated Urinary Tract Infection Treatment Global Market Report 2024, The uncomplicated urinary tract infection treatment market size is expected to see rapid growth in the next few years. It will grow to $9.16 billion in 2028 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to rising awareness campaigns, increasing healthcare access, rising healthcare infrastructure, increasing research funding, rising pharmaceutical marketing and regulatory environment. Major trends in the forecast period include advancements in rapid diagnostic tests, innovation in drug delivery systems, demand for home diagnostic kits, development of smartphone apps, and adoption of digital health solutions.
The increase in hospital-acquired infections is expected to propel the growth of the uncomplicated urinary tract infection treatment market going forward. Hospital-acquired infections are infections that patients acquire during their stay in a hospital or other healthcare facility, not present or incubating at admission. The rise in hospital-acquired infections can be attributed to factors such as antibiotic-resistant bacteria, inadequate infection control practices, more extended hospital stays, and compromised immune systems of patients. The rising number of hospital-acquired infections underscores the critical need for robust urinary tract infection treatment strategies within healthcare settings, driving innovation and investment in this area to meet growing clinical demands effectively. For instance, in June 2024, according to the Australian Institute of Health and Welfare, an Australia-based governmental department, there were 1,668 cases of staphylococcus aureus bloodstream infections (SABSI) reported during 22.5 million patient care days in public hospitals, resulting in a rate of 0.74 SABSI cases per 10,000 patient days. Therefore, the increase in hospital-acquired infections is driving the growth of the uncomplicated urinary tract infection treatment market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=17288&type=smp
The uncomplicated urinary tract infection treatment market covered in this report is segmented –
1) By Drug Class: Gepotidacin, Probenecid, Sulfonamide, Tetracycline, Nitrofuran
2) By Source Of Infection: Hospital-Acquired Urinary Tract Infection (UTI), Community-Acquired Urinary Tract Infection (UTI)
3) By Gender: Male, Female
4) By Distribution Channel: Hospital Pharmacies, Gynaecology And Urology Clinics, Retail Pharmacies, Online Drug Stores
Major companies operating in the uncomplicated urinary tract infection treatment market focus on developing innovative products such as parenteral carbapenem antibacterial agents to enhance treatment efficacy and address rising antibiotic resistance. A parenteral carbapenem antibacterial agent is a broad-spectrum antibiotic administered by injection to treat severe or resistant bacterial infections. For instance, in September 2021, BDR Pharmaceuticals Internationals Pvt. Ltd., an India-based pharmaceutical company, launched BIAPENEM, a carbapenem antibiotic to treat intra-abdominal, lower respiratory, or urinary tract infections. It is a parenteral carbapenem antibacterial agent with a broad spectrum of antibacterial activity, making it suitable for treating various infections.
The uncomplicated urinary tract infection treatment market report table of contents includes:
1. Executive Summary
2. Uncomplicated Urinary Tract Infection Treatment Market Characteristics
3. Uncomplicated Urinary Tract Infection Treatment Market Trends And Strategies
4. Uncomplicated Urinary Tract Infection Treatment Market - Macro Economic Scenario
5. Global Uncomplicated Urinary Tract Infection Treatment Market Size and Growth
...................
32. Global Uncomplicated Urinary Tract Infection Treatment Market Competitive Benchmarking
33. Global Uncomplicated Urinary Tract Infection Treatment Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Uncomplicated Urinary Tract Infection Treatment Market
35. Uncomplicated Urinary Tract Infection Treatment Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
